This month we are excited to announce that MSD
has joined the Milner Therapeutics Consortium
as our 12th pharma partner.
This coincides with the company’s investment in a new Discovery Centre in London, located in the heart of the Knowledge Quarter. MSD scientists in the UK are working towards a shared purpose: to drive medical advances against some of the most challenging diseases facing ageing populations. James Duce (Director of Discovery Research, London) and Richard Reschen (Associate Director, Business Development & Licensing, Europe) will sit on the Milner Innovation Board, bringing new expertise and representing the company’s scientific interests across key therapeutic areas, including neuroscience and oncology.